LSZ Stats & Data
DUKNIHFTDAXJON-CTQRGLTFSA-NReceptor Profile
Receptor Actions
History & Culture
1980s–2002
The development of LSZ traces back to efforts by David E. Nichols and colleagues at Purdue University to create conformationally restricted analogues of LSD for use as pharmacological research tools. The goal was to better understand how LSD orients itself when binding to the serotonin 5-HT2A receptor and to map the receptor's topography more precisely. Initial attempts in the 1980s by Nichols and Robert Oberlender utilized LA-Aziridine, a closely related compound, but this proved to be highly chemically unstable, precluding in-vivo studies. The team eventually succeeded with LSZ, a rigid analogue in which LSD's N,N-diethylamide group has been constrained into a 2,4-dimethylazetidine ring structure. This modification introduces two additional chiral centers, resulting in three possible diastereomers. The compound was first described in the scientific literature in 2002. Research determined that the (S,S)- isomer, designated LA-SS-Az, demonstrated the greatest potency for 5-HT2A receptor activation and psychedelic-like effects in animal models. Later crystallographic studies revealed that LSD's conformation within the closely related 5-HT2B receptor is essentially superimposable with the structure of LA-SS-Az. LSZ remains one of the only known LSD analogues with modifications at the amide position that retains similar or greater psychedelic potency.
2000–present
According to accounts from Krystle Cole in an interview with journalist Hamilton Morris, the clandestine LSD manufacturers William Leonard Pickard and Gordon Todd Skinner reportedly synthesized and experimented with a psychedelic they referred to as "diazedine" around the year 2000. Cole described the compound as "crazy, but nothing earth-shattering." The pair reportedly had ambitions to produce and distribute the substance as an alternative to LSD but encountered difficulties scaling the synthesis due to high production costs and low yields. Notably, Pickard had been a student of Nichols at Purdue University and was aware of the LSZ research prior to its publication. Morris has speculated that "diazedine"—a name that appears to be a contraction of "dimethylazetidine"—is very likely the same compound as LSZ, though this has never been officially confirmed. Persistent rumors also suggest that LSZ may have been distributed on blotter paper under the name "λ" (lambda) during this period, though this similarly remains unverified.
2012–2013
LSZ had little documented history of human use prior to 2012, when it began appearing on research chemical markets in the United Kingdom. The compound gained wider international availability through a cluster of mail-order vendors specializing in novel psychedelics that emerged during this period. The substance was first definitively identified as a novel designer drug in Europe in December 2013. It is known to have been manufactured and distributed by Lizard Labs, a now-defunct company that specialized in lysergamide production through the 2010s and into the 2020s. Following its initial emergence, LSZ developed a reputation as a popular alternative to LSD and other lysergamides within the psychedelic research chemical community.
Subjective Effects
Physical
- Bodily control enhancement
- Nausea
- Pupil dilation
- Spontaneous tactile sensations
- Stimulation
- Tactile enhancement
Cognitive
- Analysis enhancement
- Conceptual thinking
- Creativity enhancement
- Delusions
- Emotion enhancement
- Immersion enhancement
- Memory suppression
- Ego death
- Mindfulness
- Novelty enhancement
- Personal bias suppression
- Spirituality enhancement
- Thought acceleration
- Thought disorganization
- Thought loops
- Time distortion
- Unity and interconnectedness
- Wakefulness
Sensory
- Enhancements
- Distortions
- Hallucinations
- Drifting: (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Tracers
- Colour enhancement
- Pattern recognition enhancement
- Visual acuity enhancement
- Transformations
- Internal hallucinations: (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)
Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).
Toxicity
PsychonautWikiThe toxicity and long-term health effects of recreational LSZ do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because LSZ is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried LSZ suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.
Effect Profile
Curated + 11 ReportsStrong visuals and headspace with mild body load
Community Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 11 experience reports (11 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 11 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 8
Adverse Effects 4
Show 2 neutral or unclassified mentions
Dosage Distribution
Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.
Real-World Dose Distribution
ErowidFrom 18 of 22 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.
Sublingual (n=5)
Oral (n=13)
Common Combinations
Most co-occurring substances, as a share of all 24 reports filed under LSZ; whiskers are 95% intervals
Form / Preparation
Most common forms and preparations, as a share of the 22 reports that give one; whiskers are 95% intervals
Body-Weight Dosing
Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.
Redose Patterns
Redosing behavior across 22 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Denmark | Illegal | Specifically named on the list of controlled substances as of August 25, 2015. Possession, distribution, and manufacture are prohibited. |
| Germany | NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Controlled under the New Psychoactive Substances Act as of July 18, 2019. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalty. |
| Japan | Controlled | Regulated under the Pharmaceutical Affairs Law (Pharmaceutical and Medical Device Act). Possession and sale are illegal without proper authorization. |
| Latvia | Illegal (LSD analogue) | Controlled as a structural analogue of LSD under an amendment enacted on June 1, 2015. Although not officially scheduled by name, analogue provisions make it a controlled substance. |
| Sweden | Controlled substance | Classified as a narcotic substance as of January 26, 2016, following its emergence on the designer drug market. Manufacturing, trade, and possession are prohibited. |
| Switzerland | Controlled (Verzeichnis E) | Specifically named and added to Verzeichnis E (Schedule E) of the controlled substances ordinance as of December 1, 2015. |
| Turkey | Illegal | Classified as a controlled drug under national drug legislation. Possession, production, supply, and importation are prohibited. |
| United Kingdom | Class A (Schedule 1) | Specifically named as a controlled substance under the Misuse of Drugs Act 1971 as of January 7, 2015. As a Class A substance, it carries the most severe penalties for possession, supply, and production. |
| United States | Unscheduled (Federal Analogue Act applies) | LSZ is not specifically scheduled at the federal level. However, as a structural analogue of LSD, it may be prosecuted under the Federal Analogue Act when sold for human consumption or possessed with intent to ingest. No cases for simple possession alone have been reported. |